An association study between PPP1R1B gene and schizophrenia in the Chinese population

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 6, 2007, Pages 1303-1306

  Hu, Jian Xin ^a,b   Yu, Lan ^a,b   Shi, Yong Yong ^a,b   Zhao, Xin Zhi ^a,b   Meng, Jun Wei ^a,b   He, Guang ^a,b   Xu, Yi Feng ^c   Feng, Guo Yin ^c   He, Lin ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Case control study; Chinese population; DARPP 32; PPP1R1B; Schizophrenia

Indexed keywords

CYCLIC AMP; DOPAMINE; GLUTAMIC ACID; INHIBITOR PROTEIN; PHOSPHOPROTEIN; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE 1; REGULATOR PROTEIN; SEROTONIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; GENE; GENE DELETION; GENE SWITCHING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NEOSTRIATUM; NEUROTRANSMISSION; POINT MUTATION; PPP1R1B GENE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHINA; DNA MUTATIONAL ANALYSIS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 34447569201     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.05.014     Document Type: Article

References (25)

1. Albert K.A., Hemmings Jr. H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 59 (2002) 705-712
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3th ed (2000), American Psychiatric Association, Washington, DC 121-139
3. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 97 (2000) 6809-6814
4. Calabresi P., Gubellini P., Centonze D., Picconi B., Bernardi G., Chergui K., et al. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci 20 (2000) 8443-8451
5. Carter C.J. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86 (2006) 1-14
6. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281 (1998) 838-842
7. Foubister V. Do all paths lead to DARPP-32?. Drug Discov Today 7 (2002) 1068-1070
8. Gerber D.J., Hall D., Miyakawa T., Demars S., Gogos J.A., Karayiorgou M., et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A 100 (2003) 8993-8998
9. Greengard P., Allen P.B., and Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23 (1999) 435-447
10. Hahn L.W., Ritchie M.D., and Moore J.H. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19 (2003) 376-382
11. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 73 (2003) 34-48
12. Li C.H., Liao H.M., Hung T.W., and Chen C.H. Mutation analysis of DARPP-32 as a candidate gene for schizophrenia. Schizophr Res 87 (2006) 1-5
13. Marchini J., Donnelly P., and Cardon L.R. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 37 (2005) 413-417
14. Meyer-Lindenberg A., Straub R.E., Lipska B.K., Verchinski B.A., Goldberg T., Callicott J.H., et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 117 (2007) 672-682
15. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 100 (2003) 8987-8992
16. Ouimet C.C., Miller P.E., Hemmings Jr. H.C., Walaas S.I., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci 4 (1984) 111-124
17. Purcell S., Cherny S.S., and Sham P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19 (2003) 149-150
18. Sham P.C., and Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59 (1995) 97-105
19. Shenolikar S., and Nairn A.C. Protein phosphatases: recent progress. Adv Second Messenger Phosphoprot Res 23 (1991) 1-121
20. Shi Y.Y., and He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15 (2005) 97-98
21. Svenningsson P., Tzavara E.T., Liu F., Fienberg A.A., Nomikos G.G., and Greengard P. DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc Natl Acad Sci U S A 99 (2002) 3188-3193
22. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., and Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 99 (2002) 3182-3187
23. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., et al. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
24. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., and Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44 (2004) 269-296
25. Walaas S.I., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J Neurosci 4 (1984) 84-98